Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Webinars
  4. ESMO Deep Dive: Breast Cancer - Webinar Series

ESMO Deep Dive: Breast Cancer - Metastatic Triple Negative Breast Cancer: Refining Practice and Steering Research 2024

Aired live on 09 Oct 2024

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Presentation

Download slides

CME test

2 ESMO - MORA points

Programme

  • 9 October 2024
Welcome and introduction
Peter Schmid
What to do with early relapsers? Current concepts and ongoing research
Rebecca Dent
Where are we heading with ADCs? Ongoing research and future directions
Sara Tolaney
Is there more to come from immunotherapy?
Giampaolo Bianchini
QnA and Discussion
All speakers

Description

This ESMO Deep Dive Breast Cancer Webinar focused on Metastatic Triple Negative Breast Cancer.

This webinar was developed with the aim to provide a second, deeper layer of educational experience in emerging data related to: molecular biology and classification, translational research and biomarkers for precision medicine, and unknowns, hypotheses, and ongoing research in areas of controversy or unmet need for optimal management of patients.

It began with a brief welcome and introduction, then three lectures were delivered on: early relapses, future directions with ADCs, and ongoing research in immunotherapy. The lectures were followed by a live discussion with the speakers’ panel. 

This programme was designed to provide an overview of the latest understanding of molecular biology and the impact of targeting different pathways in the management of patients with breast cancers, offer expert opinion exchange, and provide some important considerations in this field.

Learning objectives

  • To acquire a deeper understanding of the clinical course of malignant disease of breast cancer. ​
  • To understand biological hypotheses on classification and risk stratification, ongoing/required research in therapeutics and knowledge of use of omics technologies for biomarker-enabled precision medicine for breast cancer.​
  • To develop skills and abilities for critical analysis, interpretation of research data and therapeutic strategies.​
  • To become better equipped for informed, innovative thinking and engagement in ongoing or new research projects.

Supported by

SB-Daiichi-Astrazeneca
SB-Gilead
SB-Lilly
SB-MSD
SB-Novartis

You may also be interested in...

Deep Dive: Breast Cancer

Related Links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.